- Home
- KPRX vs BGLC Comparison
KPRX vs BGLC Comparison
Compare KPRX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- BGLC
- Stock Information
- Founded
- KPRX 1998
- BGLC 2017
- Country
- KPRX United States
- BGLC Malaysia
- Employees
- KPRX N/A
- BGLC N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BGLC Medical Specialities
- Sector
- KPRX Health Care
- BGLC Health Care
- Exchange
- KPRX Nasdaq
- BGLC Nasdaq
- Market Cap
- KPRX 8.7M
- BGLC 10.4M
- IPO Year
- KPRX N/A
- BGLC N/A
- Fundamental
- Price
- KPRX $2.71
- BGLC $5.04
- Analyst Decision
- KPRX Strong Buy
- BGLC
- Analyst Count
- KPRX 1
- BGLC 0
- Target Price
- KPRX $10.00
- BGLC N/A
- AVG Volume (30 Days)
- KPRX 80.3K
- BGLC 54.1K
- Earning Date
- KPRX 08-08-2025
- BGLC 08-18-2025
- Dividend Yield
- KPRX N/A
- BGLC N/A
- EPS Growth
- KPRX N/A
- BGLC N/A
- EPS
- KPRX N/A
- BGLC N/A
- Revenue
- KPRX N/A
- BGLC $9,551,559.00
- Revenue This Year
- KPRX N/A
- BGLC N/A
- Revenue Next Year
- KPRX N/A
- BGLC N/A
- P/E Ratio
- KPRX N/A
- BGLC N/A
- Revenue Growth
- KPRX N/A
- BGLC 4.01
- 52 Week Low
- KPRX $2.25
- BGLC $2.01
- 52 Week High
- KPRX $4.18
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- KPRX 48.49
- BGLC 42.79
- Support Level
- KPRX $2.67
- BGLC $5.45
- Resistance Level
- KPRX $2.90
- BGLC $5.79
- Average True Range (ATR)
- KPRX 0.14
- BGLC 0.21
- MACD
- KPRX 0.01
- BGLC -0.06
- Stochastic Oscillator
- KPRX 39.13
- BGLC 4.94
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.